Recombinant Human CD86 Protein (His Tag)
Beta LifeScience
SKU/CAT #: BLPSN-1149
Recombinant Human CD86 Protein (His Tag)
Beta LifeScience
SKU/CAT #: BLPSN-1149
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Tag | His |
Host Species | Human |
Accession | NP_008820.2 |
Synonym | B7-2, B7.2, B70, CD28LG2, LAB72 |
Background | CD86, also known as B-lymphocyte activation antigen B7-2 (referred to as B7), is a member of the cell surface immunoglobulin superfamily. B7-2 exists predominantly as a monomer on cell surfaces and interacts with two co-stimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells, and thus induces the signal pathways which regulate T cell activation and tolerance, cytokine production, and the generation of CTL. It is indicated that contacts between B and T helper cells mediated by CD86 encourage signals for the proliferation and IgG secretion of normal B cells and B cell lymphomas. Recent study has revealed that CD86 also promotes the generation of a mature APC repertoire and promotes APC function and survival. CD86 has an important role in chronic hemodialysis, allergic pulmonary inflammation, arthritis, and antiviral responses, and thus is regarded as a promising candidate for immune therapy.Immune CheckpointImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint Detection: IP AntibodiesImmune Checkpoint Detection: FCM AntibodiesImmune Checkpoint Detection: WB AntibodiesImmune Checkpoint ProteinsImmune Checkpoint TargetsCo-inhibitory Immune Checkpoint Targets ImmunotherapyCancer ImmunotherapyTargeted Therapy |
Description | A DNA sequence encoding the extracellular domain (Met 1-His 239) of human B7-2 (NP_008820.2) was fused with a His tag at the C-terminus. |
Source | HEK293 |
Predicted N Terminal | Leu 20 |
AA Sequence | Met 1-His 239 |
Molecular Weight | The recombinant human B7-2 consists of 228 a.a. and has a predicted molecular mass of 26.2 kDa. In SDS-PAGE, the apparent molecular mass of rhB7-2 is approximately 55-60 kDa due to glycosylation. |
Purity | >97% as determined by SDS-PAGE |
Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method |
Bioactivity | Measured by its binding ability in a functional ELISA. Immobilized human CD86 at 20 ug/ml (100 ul/well) can bind human CD28 with a linear ranger of 32-800 ng/ml. |
Formulation | Lyophilized from sterile PBS, pH 7.4. |
Stability | The recombinant proteins are stable for up to 1 year from date of receipt at -70°C. |
Usage | For Research Use Only |
Storage | Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |